Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRD9 degraders CAN-25-5405-ETR1

ABSTRACT: BRD9 degraders unleash GBAFCHromatin Remodeling Activity in Synovial Sarcoma

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell

DISEASE(S): Acute Leukemia

SUBMITTER: Hans Voshol

LAB HEAD: Johannes Voshol

PROVIDER: PXD079388 | Pride | 2026-06-23

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	BRD9_paper_Fig2DE.csv	Csv
	BRD9_sample_annotation_figS2A.pdf	Pdf
	BRD9_tc_24h.sky	Other
	BRD9_tc_24h.sky.view	Other
	BRD9_tc_24h.skyd	Other

Items per page:

1 - 5 of 12

Similar Datasets

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [ChIP-seq]

Project description:We used a CRISPR-based screening approach to identify functional vulnerabilities in pediatric sarcoma cell types, identifying BRD9 as an important dependency in synovial sarcoma cells.

2018-11-01 | GSE113228 | GEO

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [RNA-seq]

2018-11-01 | GSE113227 | GEO

ATAC-seq of synovial sarcoma cell lines treated with the BRD9 PROTAC degrader WA-68

Project description:Synovial sarcoma (SyS) is driven by the SS18::SSX fusion oncoprotein, which incorporates into GBAF chromatin remodeling complexes and creates a dependency on BRD9. To investigate the effects of BRD9 loss, we performed ChIP-seq, ATAC-seq, and RNA-seq in SyS models following BRD9 degradation. ChIP-seq shows reduced GBAF occupancy at target loci, while ATAC-seq reveals maintained or increased chromatin accessibility. RNA-seq demonstrates sustained or elevated expression of target genes. These results indicate that BRD9 is not required for GBAF assembly but instead restrains its remodeling activity, providing a mechanistic explanation for the limited efficacy of BRD9-targeted therapies in SyS.

2026-06-24 | GSE328410 | GEO

RNA-seq of HS-SY-II synovial sarcoma cells treated with the BRD9 PROTAC degrader WA-68 across a time course

2026-06-24 | GSE328412 | GEO

Depletion of BRD9-mediated R-loop accumulation inhibits leukemia cell growth via transcription-replication conflict

Project description:Bromodomain-containing protein 9 (BRD9) has emerged as a promising therapeutic target for blood cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and multiple myeloma (MM). PROTAC-based BRD9 degraders effectively hamper the growth and survival of leukemia cells; however, the underlying mechanism of these BRD9 degraders remains unclear. In this study, we demonstrated that depletion of BRD9 triggers DNA damage via R-loop accumulation, leading to conflicts between transcription and replication processes. Replication stress inhibits the proliferation of leukemia cells and promotes their differentiation. Mechanistically, BRD9 plays a pivotal role in recruiting BRD2 and BRD4 to chromatin through direct interactions, which is critical for preventing R-loop formation during transcription. Depletion of BRD9 in leukemia cells reduces the occupancy of BRD2 and BRD4 at R-loop-prone sites, thus promoting R-loop accumulation, transcription-replication collision, excessive DNA damage, and ultimately, the demise of cancer cells. These findings provide valuable insights into the mechanisms by which BRD9 degraders function as effective therapies for leukemia mediated by the pathological accumulation of R-loops.

2025-07-16 | GSE300622 | GEO

ChIP-seq of GLTSCR1 and SS18::SSX fusion in HS-SY-II synovial sarcoma cells treated with the BRD9 PROTAC degrader WA-68 across a time course

2026-06-24 | GSE328411 | GEO

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

Project description:Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

| PRJNA450475 | ENA

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [ChIP-seq]

Project description:Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [ChIP-seq]

| PRJNA450476 | ENA

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [RNA-seq]

Project description:Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [RNA-seq]

| PRJNA450466 | ENA